Current Issues of Pharmacy and Medical Sciences

Does additional HIPEC help after CRS in peritoneal disseminated gastric cancer?

Curr Issues Pharm Med Sci., Vol. 30, No. 4, 187-189

Beate Rau*, Eva Pachmayr, Dusan Klos, Peter Thuss-Patience, Andreas Brandl

Chirurgische Klinik, Charité - Universitätsmedizin Berlin, Charité Campus Mitte Charité Platz 1, 10117 Berlin, Germany

DOI: 10.1515/cipms-2017-0035


The incidence of synchronous or metachronous peritoneal metastases (PM) in patients with locally advanced gastric cancer is high, and associated with a poor prognosis. The recommended therapeutic option for these patients is systemic chemotherapy and leads to a median of 7-8 months. However, new approaches like cytoreductive surgery and hyperthermic intraperitoneal chemotherapy might help to improve the median survival in selected patients. 
Indications, patient selection and the choice of the chemotherapeutic agent are described in this manuscript, as well as an overview of the most recent literature about this topic.


gastric adenocarcinoma, hyperthermic intraperitoneal chemotherapy (HIPEC), peritoneal metastasis, peritoneal carcinomatosis, GASTRIPEC trial


July 2019

Mon Tue Wed Thu Fri Sat Sun
01 02 03 04 05 06 07
08 09 10 11 12 13 14
15 16 17 18 19 20 21
22 23 24 25 26 27 28
29 30 31